Presidio Medical vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Presidio Medical develops an ultra-low frequency (ULF) spinal cord stimulation platform for nociceptive lower back pain; raised $102M total including $72M Series C from Deerfield; 95% responder rate in trials.
About
Presidio Medical is a clinical-stage medical technology company developing a next-generation neuromodulation platform for treating chronic nociceptive lower back pain. Founded in 2017 and headquartered in South San Francisco, California, the company''s Ultra Low Frequency (ULF™) Neuromodulation System delivers precisely calibrated, ultra-low frequency electrical pulses through spinal cord stimulation (SCS) electrodes to inhibit neuronal pain responses localized to the lower back — without relying on paresthesia (the tingling sensation associated with older SCS devices).
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.